Agenus Inc. (AGEN) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Agilent Inc. fourth quarter and full year 2023 results conference call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. At this time, I would like to turn the conference over to Zach Arman, Head of Investor Relations. Please go ahead. Thank you, Audra, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory, and commercial plans and timelines. as well as timelines for data release and partnership opportunities, among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks. Joining me today are Dr. Garrow Arman, Chairman and Chief Executive Officer, Dr. Steven O'Day, Chief Medical Officer, and Christine Klaskin, Vice President of Finance. Dr. Robin Taylor, Chief Commercial Officer, and Dr. Todd Yancey, Chief Strategic Advisor, will be participating in the Q&A session. Now, I'd like to turn the call over to Gero to highlight our progress in 2023 and to speak to our outlook for 2024. Gero. Thank you very much. Ladies and gentlemen, today it is with great enthusiasm that we gather to share the remarkable ...